The FTC has taken unconstitutional actions in publishing a report that ignores the evidence provided by our company and other [pharmacy benefit managers], demonstrates clear ideological bias and advances a false and damaging narrative—narrative that could harm the health care system by removing essential checks and balances which would result in higher drug prices for American consumers,

Express Scripts has filed a lawsuit against the Federal Trade Commission (FTC) over the agency's recent report on PBMs, which highlighted their contribution to soaring drug prices in the U.S., Reuters reported Tuesday.

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for patients

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.

The Federal Trade Commission said on Friday that it had taken legal action against the three largest pharmacy benefit managers, accusing the drug middlemen of inflating insulin prices and steering patients toward higher-cost insulin products to increase their profits.

Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.

Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.